Aptar Pharma Recognises World Parkinson's Day with a New White Paper Focused on Blood-Brain Barrier Drug Delivery
Aptar Pharma presents a new scientific white paper, following its recent roundtable held in Paris, France.
The goal of this roundtable was to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood-brain barrier (BBB) and successfully treating a host of central nervous system (CNS) diseases. The CNS, which comprises the brain, spinal cord and a complex system of neurons, integrates and responds to sensory information, playing a key role by coordinating body function. Diseases such Parkinson’s and Alzheimer’s are CNS disorders that affect a growing population.
Although many molecules can be used to treat brain and more generally, CNS diseases, today, only 1% of these molecules can cross the BBB, a “firewall” that allows the passage of oxygen and nutrients but blocks the entrance of what it considers harmful or toxic molecules into the brain. The challenge therefore lies in identifying potential routes for drug delivery, hence the title of the roundtable: “Crossing the Blood-Brain Barrier, Which Route to Take?”
Aptar Pharma’s scientific roundtable brought together a panel of six eminent international key opinion leaders (KOLs) specialized in brain and CNS therapies:
• Prof. Alexandre Carpentier, PhD and Scientific Consultant, Hôpital Pitié-
Salpetrière & Carthera, France
• Prof. Margareta Hammarlund-Udenaes, Head, Translational PKPD Group,
Uppsala University & Udenaes Consulting, Sweden
• Prof. Kewal Jain, Scientific Consultant, Jain Pharmabiotech, Switzerland
• Dr Jaap Rip, Senior Scientist, BBB Therapeutics, the Netherlands
• Dr Frédéric Sedel, CEO, Medday Pharma, France
• Dr Jasper Stevens, Pharmacometrician, Centre for Human Drug Research, Leiden, the Netherlands.
During this one-day meeting, these scientific experts shared their knowledge and debated several key themes, structured around the following:
• Understanding the background and unmet medical needs
• Investigating the various delivery routes via which drugs can cross the BBB
• Exploring the pros and cons of various approaches currently adopted to delivery drugs to the CNS.
In addition, the KOLs discussed various possible approaches to deliver drugs to the CNS or brain, both conventional and innovative, including the use of receptor technologies, implantable medical devices and nose to brain (N2B) drug transport.
Based on the discussions and input from participants, Aptar Pharma prepared a scientific publication entitled “Crossing the Blood-Brain Barrier, Which Route to Take?”
“All of the experts at our scientific roundtable confirmed the fact that delivering drugs safely and efficaciously to the brain and CNS remains a challenge. In fact, a major unmet medical need exists, and the market offers very attractive opportunities for drug delivery solutions that guarantee safety and efficacy, and are patient and caregiver-friendly,” said Hervé Pacaud, Business Development Director, Aptar Pharma Prescription Division.
He concluded: “By organizing this scientific event, and with the input from the KOLs, Aptar Pharma has identified this unmet medical need and determined ways to optimize treatments for patients.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance